AIR Option 1: Technology Translation Development of a Prototype Solubility Enhancing Formulation for Improved drug Delivery using novel Cellulose Derivatives.

AIR 选项 1：技术转化开发原型溶解度增强制剂，以使用新型纤维素衍生物改善药物输送。

• 批准号: 1312157
• 负责人: Lynne Taylor
• 金额: $ 15万
• 依托单位: Purdue University
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-05-01 至 2016-10-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1312157&HistoricalAwards=false
• 关键词: AIR; Option; Technology; Translation; Development

This PFI: AIR Technology Translation project focuses on translating our recent discovery of pharmaceutical crystallization inhibitors based on novel cellulose omega-carboxyalkanoates to improve the delivery of poorly water soluble drugs by formulating amorphous solid dispersions with enhanced processing and drug delivery characteristics. The translated novel polymeric materials have the following unique features: tailored amphiphilicity and high degree of substitution with carboxylic acid groups that provides exemplary crystallization inhibition of supersaturated solutions of hydrophobic drugs when compared to the leading competing polymer, hydroxypropyl methylcellulose acetate succinate, used in the formulation of amorphous solid dispersions in this market space. The project accomplishes this goal by synthesis of novel derivatives of cellulose designed to interact with poorly water soluble drugs which will be used in prototype amorphous solid dispersions formulations which are expected to lead to elevated concentrations of the drug and ultimately improved delivery of the therapeutic agent to the patient. Demonstration of the successful production of prototype formulations using common processing techniques will lead to partnerships and licensing agreements with specialty chemical and pharmaceutical companies. The potential economic impact is expected to be improved efficiency of the drug development process in the next decade, which will contribute to the U.S. competitiveness in the area of drug development. The societal impact, long term, will be the availability of new and improved medicines that might otherwise have never been made available to the public because of their poor aqueous solubility.

该 PFI：AIR 技术翻译项目的重点是转化我们最近发现的基于新型纤维素 omega-羧基链烷酸酯的药物结晶抑制剂，通过配制具有增强的加工和药物递送特性的无定形固体分散体来改善水溶性差的药物的递送。 转化的新型聚合物材料具有以下独特特征：定制的两亲性和羧酸基团的高度取代，与配方中使用的主要竞争聚合物醋酸琥珀酸羟丙甲基纤维素相比，可对疏水性药物的过饱和溶液提供示范性的结晶抑制作用该市场空间中的非晶态固体分散体。 该项目通过合成新型纤维素衍生物来实现这一目标，这些衍生物旨在与水溶性差的药物相互作用，这些衍生物将用于原型无定形固体分散体制剂，预计将导致药物浓度升高，并最终改善治疗剂的递送。病人。使用通用加工技术成功生产原型配方的示范将导致与特种化学品和制药公司建立合作伙伴关系并签订许可协议。潜在的经济影响预计将是未来十年药物开发过程效率的提高，这将有助于提高美国在药物开发领域的竞争力。 从长远来看，社会影响将是新的和改进的药物的出现，否则这些药物可能由于水溶性差而永远无法向公众提供。